Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Senesco, Alcon, and More

Premium

Title: Inhibition of Apoptosis-specific eFI-5A with Antisense Oligonucleotides and siRNA as Anti-inflammatory Therapeutics

Patent Number: 8,754,057

Filed: May 2, 2011

Lead Inventor: John Thompson, Senesco Technologies


Title: Use of miR-30e to Treat Vascular Lesions

Patent Number: 8,754,059

Filed: Aug. 25, 2011

Inventor: Lina Shehadeh, University of Miami


Title: Therapeutic Compositions

Patent Number: 8,754,201

Filed: March 10, 2010

Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals


Title: RNAi-related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis

Patent Number: 8,754,202

Filed: June 27, 2011

Inventor: Jon Chatterton, Alcon


Title: Human microRNAs and Methods for Inhibiting Same

Patent Number: 8,754,203

Filed: May 11, 2012

Lead Inventor: Thomas Tuschl, Rockefeller University